A detailed history of Forbes J M & CO LLP transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Forbes J M & CO LLP holds 48,401 shares of NVCT stock, worth $252,653. This represents 0.03% of its overall portfolio holdings.

Number of Shares
48,401
Previous 47,419 2.07%
Holding current value
$252,653
Previous $300,000 1.33%
% of portfolio
0.03%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$6.16 - $7.23 $6,049 - $7,099
982 Added 2.07%
48,401 $304,000
Q2 2024

Jul 30, 2024

BUY
$5.98 - $8.25 $80,245 - $110,706
13,419 Added 39.47%
47,419 $300,000
Q3 2023

Nov 02, 2023

SELL
$12.89 - $16.29 $425,370 - $537,570
-33,000 Reduced 49.25%
34,000 $438,000
Q2 2023

Aug 03, 2023

BUY
$12.62 - $18.4 $845,540 - $1.23 Million
67,000 New
67,000 $1.07 Million

Others Institutions Holding NVCT

About Nuvectis Pharma, Inc.


  • Ticker NVCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,642,500
  • Market Cap $76.4M
  • Description
  • Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...
More about NVCT
Track This Portfolio

Track Forbes J M & CO LLP Portfolio

Follow Forbes J M & CO LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Forbes J M & CO LLP, based on Form 13F filings with the SEC.

News

Stay updated on Forbes J M & CO LLP with notifications on news.